** Hong Kong-listed shares of RemeGen Co 9995.HK rise 5.3% to HK$84.65, their highest point since December 2021, and on course for second session of gains
** Shanghai-listed stock 688331.SS climbs 5.6% to 83.93 yuan, their highest level since February 2023
** RemeGen says it has granted Santen Pharmaceutical Co's 4536.T unit Santen Pharmaceutical (China) the exclusive rights to develop, manufacture and commercialize the company's RC28-E Injection in Greater China, South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia and Malaysia
** Company shall receive from Santen China an upfront payment of 250 million yuan ($34.79 million), development and regulatory milestone payments of up to 520 million yuan, and sales milestone payments of up to 525 million yuan
** RemeGen says it will also receive tiered sales royalties ranging from high single-digit to double-digit percentages based on product sales within the licensed territories
** RemeGen's developed RC28-E Injection is a drug for ocular neovascular diseases
** YTD, Hong Kong stock up 483.3%, Shanghai shares up 172.7%
($1 = 7.1858 Chinese yuan)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.